What does the evidence say about Chicory Root Blood Glucose Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Chicory Root Blood Glucose Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - 1 2 [,] 3 6 [–] Hemoglobinopathies are among the most prevalent monogenic disorders worldwide, with an estimated 1–5% of the global population carrying genetic mutations associated with thalassemia. [Ansari Damavandi Shahla (2025); evidence level 2] - β-thalassemia, characterized by reduced or absent synthesis of β-globin chains, is predominantly found in regions such as the Mediterranean, the Middle East, and India. [Ansari Damavandi Shahla (2025); evidence level 2] - Furthermore, individuals with thalassemia demonstrate increased intestinal iron absorption, and patients with more severe forms of the disease may experience iron deposition in the reticuloendothelial system as a consequence of repeated transfusions. [Ansari Damavandi Shahla (2025); evidence level 2] - Clinically, chRG-I was well-tolerated and slightly improved stool consistency compared to placebo. [Kerezoudi EN (2026); evidence level 4] - In an intestinal barrier challenge model, chRG-I fermentates (a pool of metabolites including SCFA and fragments of chRG-I) protected barrier integrity, modulated the cytokine milieu away from a predominantly pro-inflammatory response, as characterized by increased IL4 and IL22 and reduced IL9, IL17A, and IL21. [Kerezoudi EN (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.